⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTLA News
Intellia Therapeutics, Inc
Graph AI Raises $13.3M Series A to Scale the First AI-Native Operating System for Patient Safety
prnewswire.com
NVDA
GOOG
MSFT
AMZN
META
IBM
ORCL
CRM
ADBE
INTC
AMD
QCOM
AMAT
MU
SMCI
ASML
LRCX
KLAC
TER
SNPS
CDNS
PANW
CRWD
DDOG
PLTR
SNOW
AI
UPST
SOFI
COIN
RIOT
MARA
PLUG
FCEL
ROKU
NFLX
DIS
CMCSA
TCOM
BABA
JD
PDD
NIO
LI
TSLA
RIVN
LCID
GM
F
STLA
VWAGY
HON
GE
BA
LMT
RTX
GD
NOC
AVAV
KBR
BWXT
XOM
CVX
SHEL
BIDU
NET
FTNT
CSCO
HPQ
DELL
LEN
DHI
NVR
PHM
TMHC
MTH
KBH
BKH
ESNT
MTG
WFG
RGA
AGNC
TWO
PSEC
ARCC
BX
KKR
APO
CME
ICE
MSCI
SPGI
EQIX
AMKR
WDC
SE
MELI
AMGN
GILD
BMY
PFE
MRK
LLY
ABBV
REGN
VRTX
BIIB
AZN
SNY
NVS
ROG
TEVA
BHC
ALKS
IRTC
EXAS
CRIS
EDIT
NTLA
BNTX
MRNA
ALNY
BTAI
NVO
LULU
SIRI
SPOT
PTON
GOOGL
ZS
XPEV
Rare Disease Genome Editing Market to Hit USD 12.60 Billion by 2035, Growing at a CAGR of 11.28% - SNS Insider
globenewswire.com
NTLA
BEAM
CRSP
VRTX
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
globenewswire.com
NTLA
Replit ouvre son premier bureau international à Londres
prnewswire.com
MSFT
GOOG
ADBE
ACN
V
Z
NVDA
AMZN
META
IBM
ORCL
CRM
INTC
AMD
QCOM
MU
AMAT
ASML
TXN
ADI
NXPI
LRCX
KLAC
CDNS
SNPS
MCHP
ON
WDC
SE
PLTR
UPST
COIN
BNTX
MRNA
GILD
BMY
AMGN
REGN
LLY
BIIB
VRTX
AZN
XOM
CVX
SHEL
BABA
JD
NTES
PDD
BIDU
MELI
NIO
LI
XPEV
RIVN
TSLA
PLUG
FCEL
SPCE
CRSP
EDIT
NTLA
ALGN
EXAS
TDOC
ROKU
PYPL
HOOD
MARA
RIOT
2026 RNAi Therapeutics Market Report (3rd Edition): Analysis by Type of RNAi Molecule, Therapeutic Area, Route of Administration, Key Geographical Regions, Sales Forecast and Leading Industry Players to 2035
globenewswire.com
ALNY
ARWR
NVO
NVS
BIIB
REGN
GILD
MRK
BMY
ABBV
AMGN
AZN
PFE
SNY
TEVA
BHC
CRSP
EDIT
NTLA
SRPT
SLN
$5.29 Billion Genome Editing Market Analysis and Leading Industry Players, 2026: Trends and Growth Forecast to 2035
globenewswire.com
ARCT
BTAI
CRSP
EDIT
NTLA
VOR
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NTLA
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
globenewswire.com
NTLA